RxDoctor Payments DataLook up a doctor →

Adonis Al Botros, MD

Psychiatry · Oklahoma City, OKNPI 1316994551

Payments from drug & device makers

$72,714in general payments, 2019–2025

Across 1,303 payments — averaging $55.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$26K
  • AbbVie$19K
  • Johnson & Johnson$6K
  • Sunovion Pharmaceuticals Inc.$5K
  • Teva Pharmaceuticals USA, Inc.$3K
  • Indivior Inc.$2K
  • plus $12K from 29 others

What the payments were for

  • Speaking & faculty fees$47,37965%
  • Travel & lodging$3,0954%
  • Food & beverage$21,91330%
  • Education$3270%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$72,714 in reported general payments places this provider in the 95th percentile of 328 psychiatry providers in Oklahoma.

See all psychiatry providers in Oklahoma

Medicare billing

Part B allowed, 2024
$202,930
Medicare patients
253
Services billed
3,113

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Austedo XrDeutetrabenazine18$113,131
VraylarCariprazine Hcl65$92,921
Invega SustennaPaliperidone Palmitate34$89,703
RexultiBrexpiprazole37$56,746
AristadaAripiprazole Lauroxil11$34,619
CaplytaLumateperone Tosylate13$21,990
VyvanseLisdexamfetamine Dimesylate42$16,352
Aripiprazole347$14,248
TrintellixVortioxetine Hydrobromide23$12,624
Clozapine80$5,660
Quetiapine Fumarate402$5,435
Duloxetine Hcl294$5,216
DayvigoLemborexant15$5,099
BelsomraSuvorexant13$5,037
Bupropion XlBupropion Hcl265$4,123

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo Xr$3,023$113,13118 claims
AbbVieVraylar$18,695$92,92165 claims
Johnson & JohnsonInvega Sustenna$6,418$89,70334 claims
Otsuka America Pharmaceutical, Inc.Rexulti$1,530$56,74637 claims
Alkermes, Inc.Aristada$1,707$34,61911 claims
Takeda Pharmaceuticals U.S.A., Inc.Vyvanse, Trintellix$703$28,97665 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$25,834$21,99013 claims
Eisai Inc.Dayvigo$134$5,09915 claims
MerckBelsomra$114$5,03713 claims
Almatica Pharma LLCSertraline Hcl$214$3,321430 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 328 psychiatry providers in Oklahoma.

Other psychiatry in Oklahoma City

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →